openPR Logo
Press release

myriamed is a member of the international 4D Bioprinting network

09-27-2021 08:44 AM CET | Science & Education

Press release from: myriamed GmbH

4D Bioprinting

4D Bioprinting

myriamed has become a member of the ZIM innovation network 4D Bioprinting. The network, which is led by EurA AG supports concrete innovative products and new services in the field of bioprinting for applications in biology, pharmacy, and medicine. Thus, the network promotes the commercialization of the innovative technologies of the network partners by market-oriented R&D projects and establishment of new value chains for biopharmaceuticals and medicine.
Phase 1 of the network was ended in July 2021 and the network has entered Phase 2 for another 36 months.

To learn more about the network please visit:
https://bit.ly/4D_bioprinting

About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages and tissues (published for example in Tiburcy et al. 2017 and Long et al. 2018). The myriamed product portfolio is constantly evolving and based on a comprehensive IP portfolio to offer its know-how and associated services in drug development.
myriamed gives access to the following expertise:
• high quality human iPSC-derived somatic cells (myrCell) to be used in drug discovery and development.
• macroscale (3D) tissue (myrTissue) generated from the respective iPSC lines with properties of postnatal tissue for advanced screening and target validation.
• A highly parallelized phenotypic screening service (myrScreen).

myriamed has therefore two main types of activities, the generation of high-quality biological material allowing the research of new therapeutic targets, and the realization of customized phenotypic screenings.

To learn more about myriamed’s products please contact us:
http://bit.ly/myriamed_contact

About EurA AG: EurA is an international consulting company specialized in innovation and technology. Our consultants support companies, research institutions and public clients of all sizes in enabling technical innovations. We support tomorrow’s market leaders in generating ideas for innovations, developing new products and services and launching them internationally.
EurA clients benefit from the sector and industry experience as well as from the technical knowledge of our highly qualified consultants. As an expert in funding and as a leader in innovation ecosystems, we are the ideal strategic partner for business and science - certified and quality-tested.

To learn more about EurA AG please visit:
https://www.eura-ag.com

myriamed GmbH
Rudolf-Wissell-Str. 28a
37079 Göttingen
Tel.: +49 551 28878-170
Email: info@myriamed.com
Web: www.myriamed.com

myriamed – the drug development accelerator

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.
At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release myriamed is a member of the international 4D Bioprinting network here

News-ID: 2406037 • Views: 474

More Releases from myriamed GmbH

myriamed launches online shop
To deliver the best possible service to our customers, myriamed has launched its own online shop. The shop features various human iPSC derived cell types (myrCell) such as cardiomyocytes, skeletal muscle cells and stroma cells as well as various tissue types (myrTissue) such as cardiac tissue, fibrotic tissue or brain organoids. In addition, you can order our proprietary tissue culture plates (myrPlates) via the shop to cast and culture macroscale
myriamed has joined Science Exchange
Science Exchange, the leading SaaS-enabled marketplace platform for outsourced R&D services, has partnered with myriamed. Visit myriamed’s profile to inquire about our services or request a quote. There are no additional contracts required if you request on Science Exchange and you can order immediately. Please visit our profile here: http://bit.ly/myriamed_Science_Exchange About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and
myriamed is now a member of the Network for Pharma Solutions
We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development. It serves as a platform for research, development and marketing of new products, technologies and services in drug development. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in
Helping to accelerate the development of novel drugs against Covid-19 disease
Even though vaccines against Covid-19 will be available soon, artificial herd immunity via vaccination will probably not reached until the end of 2021. Thus, the current fight against Covid-19 disease heavily relies on already available drugs. Unfortunately, there is hardly any drug that fights the disease effectively. Cortisone based therapeutics are currently the ones used most frequently and most successfully. The originally promising drug Remdesivir, which has been approved for the

All 5 Releases


More Releases for Bioprinting

Skin 3D Bioprinting Market - Forecast to 2026
As per the research conducted by GME, the Skin 3D Bioprinting Market will grow with a high CAGR value over the forecast period. Browse TOC on “Global Skin 3D Bioprinting Market - Forecast to 2026" https://www.globalmarketestimates.com/market-report/global-skin-3d-bioprinting-market-3035 By Component (3D Bioprinters [Microextrusion, Inkjet 3D, Laser-Assisted, Magnetic], Bioinks [Natural, Hybrid, Synthetic]), By Material (Hydrogels, Extracellular Matrices), By End-Use (Research Organizations & Academic Institutes, Hospitals), By Region (North America, Asia Pacific, Europe, Latin
Current Bioprinting Prospects and Future Innovations
Bharat Book Bureau Provides the Trending Market Research Report on“Global Current Bioprinting Prospects and Future Innovations Market Forecast to 2019-2024”under Life Sciences Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports. Report Scope: This new BCC Research report on the topic “Current Bioprinting Prospects and Future Innovations” offers a detailed perspective on bioprinting technology, its current market and future prospects. The report provides a
3D bioprinting new booming trends in 2027
The Global 3D bioprinting Market is growing with the rapid pace; mainly due the burgeoning Healthcare Sector. According to a recent study report published by the Market Research Future, The global 3D bioprinting Market is booming and expected to gain prominence over the forecast period 3D bioprinting is the process of creating cell designs in a confined space 3D printing technologies where cell capacity and reasonability are preserved within the printed
3D Bioprinting in Global Market 2017 - 2022
This report studies 3D Bioprinting in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Organovo Holdings Inc. EnvisionTEC GmbH Nano3D Biosciences, Inc. Cyfuse Biomedical K.K. BioBots Aspect Biosystems Ltd. 3Dynamic Systems Ltd. regenHU Ltd Cellink Browse complete report
3D Bioprinting Market 2015-2025 Industry Analysis
3D Bioprinting also known as additive manufacturing is used to make three dimensional solid objects from a digital file which is achieved by using additive processes. 3D Bioprinting technology developed from prototyping in various applications for development of actual usable parts and products. 3D bioprinting market facilitates the opportunities for prosthesis, dental implants, hearing aids, contact lenses, hips implant, custom made knee and etc. that are customized and personalized according to
3D Bioprinting market : Global Overview 2022
Research Trades adds a new report package “3D Bioprinting market- Size, Share, Trends, Forecast, Growth 2022” In this report, the global 3D Bioprinting market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market